Scandinavian ChemoTech's subsidiary Vetiqure AB begins its marketing in the US
As part of the feasibility study underway in the US ahead of the launch of the company's unique TSE (Tumour Specific Electroporation) technology, intended for the treatment of pets affected by cancer, Vetiqure AB plans to participate in a number of Veterinary Conferences during the autumn.The feasibility study, which started during the summer and will lead to a successful launch strategy in the USA, will enter a new phase during the autumn, where vetIQure™ will be shown to a larger group of veterinarians for the first time. Through its presence, the company wishes to introduce and